193 related articles for article (PubMed ID: 22359591)
21. Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.
Stephenson DT; Childs MA; Li Q; Carvajal-Gonzalez S; Opsahl A; Tengowski M; Meglasson MD; Merchant K; Emborg ME
Cell Transplant; 2007; 16(3):229-44. PubMed ID: 17503735
[TBL] [Abstract][Full Text] [Related]
22. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
23. Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Metab Brain Dis; 2003 Jun; 18(2):139-46. PubMed ID: 12822832
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous composition of dopamine neurons of the rat A10 region: molecular evidence for diverse signaling properties.
Li X; Qi J; Yamaguchi T; Wang HL; Morales M
Brain Struct Funct; 2013 Sep; 218(5):1159-76. PubMed ID: 22926514
[TBL] [Abstract][Full Text] [Related]
25. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive profiling of dopamine regulation in substantia nigra and ventral tegmental area.
Salvatore MF; Pruett BS; Dempsey C; Fields V
J Vis Exp; 2012 Aug; (66):. PubMed ID: 22907542
[TBL] [Abstract][Full Text] [Related]
27. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
28. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.
Chen MK; Kuwabara H; Zhou Y; Adams RJ; Brasić JR; McGlothan JL; Verina T; Burton NC; Alexander M; Kumar A; Wong DF; Guilarte TR
J Neurochem; 2008 Apr; 105(1):78-90. PubMed ID: 17988241
[TBL] [Abstract][Full Text] [Related]
29. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
30. Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.
Sun J; Cairns NJ; Perlmutter JS; Mach RH; Xu J
Neuroscience; 2013 Sep; 248():112-26. PubMed ID: 23732230
[TBL] [Abstract][Full Text] [Related]
31. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
Adelbrecht C; Agid Y; Raisman-Vozari R
Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
[TBL] [Abstract][Full Text] [Related]
32. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
Taylor TN; Alter SP; Wang M; Goldstein DS; Miller GW
Neuropharmacology; 2014 Jan; 76 Pt A(0 0):97-105. PubMed ID: 24025942
[TBL] [Abstract][Full Text] [Related]
33. Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice.
Isenbrandt A; Morissette M; Bourque M; Lamontagne-Proulx J; Coulombe K; Soulet D; Di Paolo T
Neuropharmacology; 2021 Dec; 201():108784. PubMed ID: 34555366
[TBL] [Abstract][Full Text] [Related]
34. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease.
Saari L; Kivinen K; Gardberg M; Joutsa J; Noponen T; Kaasinen V
Neurology; 2017 Apr; 88(15):1461-1467. PubMed ID: 28283599
[TBL] [Abstract][Full Text] [Related]
35. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman AR; Bioulac B; Brotchie JM; Gross CE
J Neurosci; 2001 Sep; 21(17):6853-61. PubMed ID: 11517273
[TBL] [Abstract][Full Text] [Related]
36. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW
Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315
[TBL] [Abstract][Full Text] [Related]
37. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice.
Gainetdinov RR; Fumagalli F; Wang YM; Jones SR; Levey AI; Miller GW; Caron MG
J Neurochem; 1998 May; 70(5):1973-8. PubMed ID: 9572281
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain.
Sun J; Xu J; Cairns NJ; Perlmutter JS; Mach RH
PLoS One; 2012; 7(11):e49483. PubMed ID: 23185343
[TBL] [Abstract][Full Text] [Related]
39. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
Ekue A; Boulanger JF; Morissette M; Di Paolo T
J Neuroendocrinol; 2002 Sep; 14(9):731-6. PubMed ID: 12213134
[TBL] [Abstract][Full Text] [Related]
40. Sex differences in dopamine- and vesicular monoamine-transporter functions.
Dluzen DE; McDermott JL
Ann N Y Acad Sci; 2008 Oct; 1139():140-50. PubMed ID: 18991858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
